Moderna shares were trading 6.49% lower at $135.71 on Monday, according to Benzinga Pro data, as the stock paused near recent highs after surging over 120% in a single session following positive clinical-trial results. Moderna and development partner Merck & Co. reported positive topline results from the Phase 3 INTerpath-001 trial, which tested intismeran autogene, an experimental individualized mRNA cancer vaccine, with Merck's Keytruda in patients with high-risk Stage IIB-IV melanoma. The combination met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, extending the time patients lived without cancer returning compared with Keytruda alone. The outcome was the first positive Phase 3 result for a personalized mRNA cancer vaccine and offered a landmark proof-of-concept for Moderna's platform beyond COVID-19 and respiratory treatments. The announcement prompted Wall Street analyst upgrades and added tens of billions of dollars to Moderna's market capitalization.